cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gh Research Plc
2 own
1 watching
Current Price
$6
$-0.19
(-3.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
662.75M
52-Week High
52-Week High
14.64000
52-Week Low
52-Week Low
5.70000
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization662.75M
icon52-Week High14.64000
icon52-Week Low5.70000
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Gh Research Plc do?
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trial and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate, and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Read More
News & Events about Gh Research Plc.
Ticker Report
5 months ago
Shares of GH Research PLC (NASDAQ:GHRS Get Rating) gapped down prior to trading on Thursday . The stock had previously closed at $12.42, but opened at $11.77. GH Research shares last traded at $12.38, with a volume of 14,555 shares trading hands. Wall Street Analysts Forecast Growth Several ...
Globe Newswire
9 months ago
DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave ...
Globe Newswire
11 months ago
Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device for GH001 progressed, IND submission with this device expected in Q3 2023Phase 1 trial of GH002 in healthy volunteers (GH002-...
Ticker Report
1 year ago
Exchange Traded Concepts LLC lifted its holdings in shares of GH Research PLC (NASDAQ:GHRS Get Rating) by 373.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,885 shares of the companys stock after acquiring an ...
Frequently Asked Questions
Frequently Asked Questions
What is Gh Research Plc share price today?
plus_minus_icon
Can Indians buy Gh Research Plc shares?
plus_minus_icon
How can I buy Gh Research Plc shares from India?
plus_minus_icon
Can Fractional shares of Gh Research Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Gh Research Plc stocks?
plus_minus_icon
What is today’s traded volume of Gh Research Plc?
plus_minus_icon
What is today’s market capitalisation of Gh Research Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Gh Research Plc?
plus_minus_icon
What percentage is Gh Research Plc down from its 52-Week High?
plus_minus_icon
What percentage is Gh Research Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$6
$-0.19
(-3.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00